title: Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis.
abstract: Pancreatic and lung inflammation during acute pancreatitis is a poorly understood, but clinically important, phenomenon. The proto-oncogene Tpl2 (tumor progression locus-2) has recently been shown to have important immunomodulatory effects on some inflammatory processes, but its importance to pancreatitis has not been previously examined. Our studies were designed to (a) define the effects of Tpl2 on pancreatic and lung inflammation during pancreatitis and (b) identify mechanisms and cell types responsible for those effects. We examined pancreatitis-associated Tpl2 effects in wild type and Tpl2(-/-) mice subjected to either secretagogue-induced or bile salt-induced pancreatitis. To determine the myeloid or non-myeloid lineage of cells responsible for the Tpl2 effects, we used Tpl2(-/-) chimeric mice generated by lethal irradiation followed by bone marrow transplantation. Mechanisms responsible for the effects of Tpl2 ablation on caerulein-induced proinflammatory events were evaluated under in vivo and in vitro conditions using the techniques of electrophoretic mobility shift assay, immunoblot analysis, and quantitative reverse transcription-PCR. We found that Tpl2 ablation markedly reduced pancreatic and lung inflammation in these two dissimilar models of pancreatitis, but it did not alter pancreatic injury/necrosis in either model. The reduction in caerulein-induced pancreatic inflammation is dependent upon Tpl2 ablation in non-myeloid cells and is associated with both in vivo and in vitro inhibition of MEK, JNK, and AP-1 activation and the expression of MCP-1, MIP-2, and interleukin-6. Non-myeloid cell expression of Tpl2 regulates pancreatic inflammation during pancreatitis by mediating proinflammatory signals and the generation of neutrophil chemoattracting factors.
authors.affiliation: Department of Surgery, Tufts University School of Medicine, Boston, MA 02111, USA.
authors.forename: Gijs J D
authors.initials: GJ
authors.lastname: Van Acker
authors.forename: George
authors.initials: G
authors.lastname: Perides
authors.forename: Eric R
authors.initials: ER
authors.lastname: Weiss
authors.forename: Santasabuj
authors.initials: S
authors.lastname: Das
authors.forename: Philip N
authors.initials: PN
authors.lastname: Tsichlis
authors.forename: Michael L
authors.initials: ML
authors.lastname: Steer
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000503:physiopathology; D004195:Disease Models, Animal; D007249:Inflammation / Q000503:physiopathology*; D008168:Lung / Q000503:physiopathology*; D020930:MAP Kinase Kinase Kinases / Q000172:deficiency / Q000235:genetics / Q000502:physiology*; D051379:Mice; D018345:Mice, Knockout; D009504:Neutrophils / Q000502:physiology; D010179:Pancreas / Q000503:physiopathology*; D010195:Pancreatitis / Q000503:physiopathology*; D011518:Proto-Oncogene Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology*
chemical_list: D011518:Proto-Oncogene Proteins; D020930:MAP Kinase Kinase Kinases; C489843:Map3k8 protein, mouse